Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

Recent & Breaking News (TSX:GUD)

Knight Disposes of Shares of Pediapharm Inc.

MarketWire Canada January 13, 2017

API Is Core to Knight's Successful Investment

MarketWire Canada January 9, 2017

Knight Creates Many GUD Synergies with its Partner

MarketWire Canada December 28, 2016

Knight Therapeutics Completes Previously Announced Bought Deal of Common Shares, Including Exercise of Over-Allotment Option, for $100 million

MarketWire Canada December 22, 2016

Knight Adds New Dimension to 3D Signatures Partnership

MarketWire Canada December 19, 2016

Knight Therapeutics Announces Exclusive License Agreement with AstraZeneca for Movantik/Moventig(R) in Canada and Israel

MarketWire Canada December 15, 2016

Knight Therapeutics Announces Increase to Bought Deal Financing

MarketWire Canada December 6, 2016

Knight Therapeutics Enters into Agreement for a $75 Million Bought Deal of Common Shares

MarketWire Canada December 6, 2016

Knight Reports Third Quarter 2016 Results

MarketWire Canada November 10, 2016

Knight to Present at the 15th Annual CIBC Eastern Institutional Investor Conference in Montreal

MarketWire Canada September 19, 2016

Ink Dry on 3D Signatures Partnership with Knight

MarketWire Canada September 9, 2016

Knight Therapeutics Inc.: INTEGA Skin Primed for Crescita (Italian for Growth)

MarketWire Canada September 1, 2016

A Knight is Reborn

MarketWire Canada August 17, 2016

Knight Therapeutics Inc.: In the Beginning of a Genesys Partnership

MarketWire Canada August 16, 2016

Knight Medison Relationship Continues to Pay Dividends

MarketWire Canada August 15, 2016

Knight Lends a Second Hand to Bloom Burton Debt Fund

MarketWire Canada August 12, 2016

Knight Reports Second Quarter 2016 Results

MarketWire Canada August 11, 2016

SIFI S.p.A. and Knight Therapeutics Announce Canadian License Agreement for NETILDEX(TM)

MarketWire Canada August 2, 2016

Knight Acquires Minor Stake in Pediapharm

MarketWire Canada July 15, 2016

Knight and Ember Expand Distribution Partnership

MarketWire Canada July 6, 2016